This company listing is no longer active
CALTX Stock Overview
A commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Calliditas Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 208.00 |
| 52 Week High | SEK 208.80 |
| 52 Week Low | SEK 80.80 |
| Beta | 1.46 |
| 11 Month Change | 0.29% |
| 3 Month Change | 1.07% |
| 1 Year Change | 114.43% |
| 33 Year Change | 115.32% |
| 5 Year Change | 263.64% |
| Change since IPO | 342.60% |
Recent News & Updates
Recent updates
Analysts Have Lowered Expectations For Calliditas Therapeutics AB (publ) (STO:CALTX) After Its Latest Results
Feb 24
Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Jan 12Market Might Still Lack Some Conviction On Calliditas Therapeutics AB (publ) (STO:CALTX) Even After 42% Share Price Boost
Dec 22Is Calliditas Therapeutics (STO:CALTX) Weighed On By Its Debt Load?
Sep 22What You Need To Know About The Calliditas Therapeutics AB (publ) (STO:CALTX) Analyst Downgrade Today
Aug 19Investors Don't See Light At End Of Calliditas Therapeutics AB (publ)'s (STO:CALTX) Tunnel And Push Stock Down 26%
May 26Is Calliditas Therapeutics (STO:CALTX) Using Debt Sensibly?
Feb 24Health Check: How Prudently Does Calliditas Therapeutics (STO:CALTX) Use Debt?
Nov 25Calliditas Therapeutics AB (publ) (STO:CALTX) Analysts Just Slashed This Year's Revenue Estimates By 19%
Aug 24Is Calliditas Therapeutics (STO:CALTX) Using Too Much Debt?
Aug 03Shareholder Returns
| CALTX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 0.7% | 2.4% | 0.5% |
| 1Y | 114.4% | 7.9% | 12.3% |
Return vs Industry: CALTX exceeded the Swedish Pharmaceuticals industry which returned 65.9% over the past year.
Return vs Market: CALTX exceeded the Swedish Market which returned 21.2% over the past year.
Price Volatility
| CALTX volatility | |
|---|---|
| CALTX Average Weekly Movement | 0.4% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: CALTX has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: CALTX's weekly volatility has decreased from 12% to 0% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 222 | Renee Aguiar-Lucander | www.calliditas.se |
Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company’s lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome.
Calliditas Therapeutics AB (publ) Fundamentals Summary
| CALTX fundamental statistics | |
|---|---|
| Market cap | SEK 11.18b |
| Earnings (TTM) | -SEK 480.36m |
| Revenue (TTM) | SEK 1.60b |
7.0x
P/S Ratio-23.4x
P/E RatioIs CALTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CALTX income statement (TTM) | |
|---|---|
| Revenue | SEK 1.60b |
| Cost of Revenue | SEK 104.68m |
| Gross Profit | SEK 1.50b |
| Other Expenses | SEK 1.98b |
| Earnings | -SEK 480.36m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 11, 2024
| Earnings per share (EPS) | -8.89 |
| Gross Margin | 93.46% |
| Net Profit Margin | -30.00% |
| Debt/Equity Ratio | 920.0% |
How did CALTX perform over the long term?
See historical performance and comparison